Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

801. Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: a meta-analysis of randomized controlled trials

Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: a meta-analysis of randomized controlled trials Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: a meta-analysis of randomized controlled trials Aerobic exercise and lipids and lipoproteins in patients with cardiovascular disease: a meta-analysis of randomized controlled trials Kelley G A, Kelley K S, Franklin B CRD summary This review assessed the effects of aerobic (...) exercise on lipids and lipoproteins in adults with cardiovascular disease. Exercise increased high-density lipoprotein cholesterol and decreased triglycerides, but not total cholesterol or low-density lipoprotein cholesterol. This was a well-conducted review, however, the conclusions should have been more cautious given that the included studies appear to be of a poor quality. Authors' objectives To assess the effects of aerobic exercise on lipids and lipoproteins in adults with cardiovascular disease

2006 DARE.

802. Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Full Text available with Trip Pro

Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Annemans L, Lamotte M, Kubin M, Evers T, Verheugt F W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of low-dose aspirin (75 to 325 mg) in the primary prevention of cardiovascular disease (CVD). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients aged

2006 NHS Economic Evaluation Database.

803. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials

Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus: meta-analysis of randomised controlled trials Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2006 DARE.

804. Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention

Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Are statins created equal: evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention Zhou Z, Rahme E, Pilote L CRD summary This review assessed (...) for inclusion. The characteristics of the patients in the included studies differed. Some studies were of primary prevention while others were of secondary prevention; some included patients with and without a history of cardiovascular disease (CVD) but at high risk for cardiovascular events; and some recruited specific subgroups (men aged less than 65 years, patients aged 65 years or older, and patients with hypertension or diabetes). The studies recruited patients with varying levels of baseline

2006 DARE.

805. Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: a data analysis

Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: a data analysis Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: a data analysis Impact of rosuvastatin use on costs and outcomes in patients at high risk for cardiovascular disease in US managed care and Medicare populations: a data analysis Huse D M (...) , Song X, Ozminkowski R J, Maguire J, Williams S A, Borok G M, McDonough K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of rosuvastatin in patients at high risk of cardiovascular disease. The study

2006 NHS Economic Evaluation Database.

806. Optimising health care within given budgets: primary prevention of cardiovascular disease in different regions of Sweden

Optimising health care within given budgets: primary prevention of cardiovascular disease in different regions of Sweden Optimising health care within given budgets: primary prevention of cardiovascular disease in different regions of Sweden Optimising health care within given budgets: primary prevention of cardiovascular disease in different regions of Sweden Lofroth E, Lindholm L, Wilhelmsen L, Rosen M Record Status This is a critical abstract of an economic evaluation that meets the criteria (...) for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study compared three methods for preventing cardiovascular disease (CVD). The prevention strategies were: smoking cessation through doctors' advice; blood pressure-lowering drugs (only offered to individuals with a systolic blood pressure greater than 140 mmHg); and lipid

2006 NHS Economic Evaluation Database.

807. Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk

Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Raloxifene produced both harms and benefits in postmenopausal women, with no reduction in cardiovascular disease risk Article Text Therapeutics Raloxifene

2006 Evidence-Based Medicine

808. Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. Full Text available with Trip Pro

Sibling cardiovascular disease as a risk factor for cardiovascular disease in middle-aged adults. While parental cardiovascular disease (CVD) doubles the risk for CVD in offspring, the extent of increased risk associated with sibling CVD is unclear.To determine, using validated events, whether sibling CVD predicts outcome in middle-aged adults independent of other risk factors.The Framingham Offspring Study, an inception cohort of the Framingham Heart Study, a prospective population-based

2005 JAMA

809. Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults. Full Text available with Trip Pro

Prevalence and cardiovascular disease correlates of low cardiorespiratory fitness in adolescents and adults. Population surveys indicate that physical activity levels are low in the United States. One consequence of inactivity, low cardiorespiratory fitness, is an established risk factor for cardiovascular disease (CVD) morbidity and mortality, but the prevalence of cardiorespiratory fitness has not been quantified in representative US population samples.To describe the prevalence of low

2005 JAMA

810. Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. (Abstract)

Cardiovascular health after maternal placental syndromes (CHAMPS): population-based retrospective cohort study. Maternal placental syndromes, including the hypertensive disorders of pregnancy and abruption or infarction of the placenta, probably originate from diseased placental vessels. The syndromes arise most often in women who have metabolic risk factors for cardiovascular disease, including obesity, pre-pregnancy hypertension, diabetes mellitus, and dyslipidaemia. Our aim was to assess (...) the risk of premature vascular disease in women who had had a pregnancy affected by maternal placental syndromes.We did a population-based retrospective cohort study in Ontario, Canada, of 1.03 million women who were free from cardiovascular disease before their first documented delivery. We defined the following as maternal placental syndromes: pre-eclampsia, gestational hypertension, placental abruption, and placental infarction. Our primary endpoint was a composite of cardiovascular disease, defined

2005 Lancet

811. Combination pharmacotherapy for cardiovascular disease. (Abstract)

Combination pharmacotherapy for cardiovascular disease. Cardiovascular disease (CVD) is the major cause of death in developed countries and is rapidly becoming the major cause of death in the developing world. The increasing rates of obesity and type 2 diabetes, however, may slow the current favorable trends for deaths attributable to CVD in many developed countries. To improve control of risk factors for CVD, Wald and Law proposed a "polypill," containing a statin, a diuretic, a beta-blocker (...) , an angiotensin-converting enzyme inhibitor, aspirin, and folic acid. This combination pharmacotherapy (CP) could be made widely available without treating specific risk factors or individuals. A workshop sponsored by the Centers for Disease Control and Prevention reviewed the concept of CP for both primary and secondary prevention. Combination pharmacotherapy may prove to be efficacious but may also have side effects and poor adherence, which may be greater than or less than that of other preventive

2005 Annals of Internal Medicine

812. Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. Full Text available with Trip Pro

Estimating the high risk group for cardiovascular disease in the Norwegian HUNT 2 population according to the 2003 European guidelines: modelling study. To estimate the high risk group for cardiovascular disease in a well defined Norwegian population according to European guidelines and the systematic coronary risk evaluation system.Modelling study.Nord-Tröndelag health study 1995-7 (HUNT 2), Norway.5548 participants of the Nord-Tröndelag health study 1995-7, aged 40, 50, 55, 60, and 65 (...) .Distribution of risk categories for cardiovascular disease, with emphasis on the high risk group.At age 40, 22.5% (95% confidence interval 19.3% to 25.7%) of women and 85.9% (83.2% to 88.6%) of men were at high risk of cardiovascular disease. Corresponding numbers at age 50 were 39.5% (35.9% to 43.1%) and 88.7% (86.3% to 91.0%) and at age 65 were 84.0% (80.6% to 87.4%) and 91.6% (88.6% to 94.1%). At age 40, one out of 10 women and no men would be classified at low risk for cardiovascular

2005 BMJ

813. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. Full Text available with Trip Pro

Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. Current guidelines for cardiovascular risk detection are controversial with regard to the clinical utility of different lipid measures, non-high-density lipoprotein cholesterol (non-HDL-C), lipid ratios, apolipoproteins, and C-reactive protein (CRP).To directly compare the clinical utility of total cholesterol, low-density lipoprotein cholesterol (...) (LDL-C), HDL-C, non-HDL-C, apolipoproteins A-I and B(100), high-sensitivity CRP, and the ratios of total cholesterol to HDL-C, LDL-C to HDL-C, apolipoprotein B(100) to apolipoprotein A-I, and apolipoprotein B(100) to HDL-C as predictors of future cardiovascular events in women.Prospective cohort study of 15,632 initially healthy US women aged 45 years or older (interquartile range, 48-59 years) who were enrolled between November 1992 and July 1995. All participants were followed up over a 10-year

2005 JAMA

814. A nurse managed smoking cessation and relapse prevention programme did not reduce smoking rates at 12 months beyond rates achieved by usual care in women with cardiovascular disease Full Text available with Trip Pro

A nurse managed smoking cessation and relapse prevention programme did not reduce smoking rates at 12 months beyond rates achieved by usual care in women with cardiovascular disease A nurse managed smoking cessation and relapse prevention programme did not reduce smoking rates at 12 months beyond rates achieved by usual care in women with cardiovascular disease | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your (...) cessation and relapse prevention programme did not reduce smoking rates at 12 months beyond rates achieved by usual care in women with cardiovascular disease Article Text Treatment A nurse managed smoking cessation and relapse prevention programme did not reduce smoking rates at 12 months beyond rates achieved by usual care in women with cardiovascular disease Free Wendy Peterson , RN, PhD , Postdoctoral Fellow Statistics from Altmetric.com Sivarajan Froelicher ES, Miller NH, Christopherson DJ, et al

2005 Evidence-Based Nursing

815. Waist hip ratio independently predicted death from cardiovascular and coronary heart disease in Australian men and women Full Text available with Trip Pro

* CONCLUSIONS Waist hip ratio independently predicted death from cardiovascular disease and coronary heart disease in Australian men and women. Commentary The study by Welborn et al found that WHR was the only anthropometric factor that was independently associated with both CHD and CVD mortality in a cohort of Australian men and women. Other features of the metabolic syndrome, including BP and triglycerides, were also independently associated with CHD mortality in men. This study primarily confirms (...) Waist hip ratio independently predicted death from cardiovascular and coronary heart disease in Australian men and women Waist hip ratio independently predicted death from cardiovascular and coronary heart disease in Australian men and women | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using

2005 Evidence-Based Medicine

816. Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. (Abstract)

Impaired fasting glucose and cardiovascular outcomes in postmenopausal women with coronary artery disease. Type 2 diabetes increases risk for cardiovascular disease. Persons with impaired fasting glucose levels may also have increased risk.To evaluate the association between glucose status and cardiovascular outcomes and the effect of lowering the fasting glucose level criterion for impaired fasting glucose from a lower limit of 6.1 mmol/L (110 mg/dL) to 5.6 mmol/L (100 mg/dL).Prospective (...) cohort study.20 U.S. clinical centers.2763 postmenopausal women with established coronary heart disease (CHD) who were followed for 6.8 years.Any CHD event (nonfatal myocardial infarction or CHD death), stroke or transient ischemic attack (TIA), congestive heart failure (CHF) hospitalization, and any cardiovascular event.During follow-up, 583 women had a CHD event, 329 women had a stroke or TIA, and 348 women were hospitalized for CHF. Women with diabetes were at an approximately 75% increased risk

2005 Annals of Internal Medicine

817. Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women Full Text available with Trip Pro

Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women Article Text Treatment Oestrogen plus progestogen did not prevent cardiovascular disease in postmenopausal women Free Irene

2005 Evidence-Based Nursing

818. Secular trends in cardiovascular disease risk factors according to body mass index in US adults. Full Text available with Trip Pro

Secular trends in cardiovascular disease risk factors according to body mass index in US adults. Prevalence of obesity in the United States has increased dramatically in recent decades, but the magnitude of change in cardiovascular disease (CVD) risk factors among the growing proportion of overweight and obese Americans remains unknown.To examine 40-year trends in CVD risk factors by body mass index (BMI) groups among US adults aged 20 to 74 years.Analysis of 5 cross-sectional, nationally

2005 JAMA

819. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. Full Text available with Trip Pro

Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. Elderly persons with chronic kidney disease have substantial risk for cardiovascular mortality, but the relative importance of traditional and novel risk factors is unknown.To compare traditional and novel risk factors as predictors of cardiovascular mortality.A total of 5808 community-dwelling persons aged 65 years or older living in 4 communities in the United States participated (...) in the Cardiovascular Health Study cohort. Participants were initially recruited from 1989 to June 1990; an additional 687 black participants were recruited in 1992-1993. The average length of follow-up in this longitudinal study was 8.6 years.Cardiovascular mortality among those with and without chronic kidney disease. Chronic kidney disease was defined as an estimated glomerular filtration rate of less than 60 mL/min per 1.73 m2.Among the participants, 1249 (22%) had chronic kidney disease at baseline

2005 JAMA

820. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. (Abstract)

A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. Randomized trials have shown that low-dose aspirin decreases the risk of a first myocardial infarction in men, with little effect on the risk of ischemic stroke. There are few similar data in women.We randomly assigned 39,876 initially healthy women 45 years of age or older to receive 100 mg of aspirin on alternate days or placebo and then monitored them for 10 years for a first major (...) cardiovascular event (i.e., nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes).During follow-up, 477 major cardiovascular events were confirmed in the aspirin group, as compared with 522 in the placebo group, for a nonsignificant reduction in risk with aspirin of 9 percent (relative risk, 0.91; 95 percent confidence interval, 0.80 to 1.03; P=0.13). With regard to individual end points, there was a 17 percent reduction in the risk of stroke in the aspirin group, as compared

2005 NEJM Controlled trial quality: predicted high